Study HZC111348, a Repeat-dose Study of GW685698/GW642444 Inhalation Powder Versus Placebo in the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Latest Information Update: 28 Aug 2023
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 22 Sep 2010 Results were presented at the 20th Annual Congress of the European Respiratory Society.
- 22 Sep 2010 Results presented at the European Respiratory Society congress, according to a GSK media release.
- 10 Oct 2009 New trial record